Delricht Research

Atlanta, Georgia 30329

5 studies enrolling now · 15 studies all time

What they study most

Acute Migraine, Alopecia, Androgenetic, COVID-19, Diabetes, Type 2, Episodic Migraine, Hidradenitis Suppurativa (HS), Influenza, Major Depressive Disorder, Migraine, Obesity, Obesity and Overweight, Overweight

Studies at this site

• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Recruiting now
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• An Open-Label Study of Azetukalner in Major Depressive Disorder — Enrolling by invitation
• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza — Running, not enrolling
• Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications — Completed
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 — Completed
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) — Completed
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine — Completed
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine — Completed